SCHEMBL21366475

SCHEMBL21366475

CC(C)(C)OCc1c(C(N)=O)cnn1-c1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
RIPK2 O43353 1/20 0.55
NR4A3 Q92570 1/20 0.52
ALDH1A1 P00352 7/20 0.47
HPGD P15428 1/20 0.47
SLC9A1 P19634 2/20 0.45
SLC9A2 Q9UBY0 2/20 0.45
MAPK1 P28482 4/20 0.45
KDM4E B2RXH2 1/20 0.44
MAPT P10636 3/20 0.43
POLB P06746 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
MAPK14 Q16539 1/20 0.43
GAA P10253 1/20 0.42
KEAP1 Q14145 1/20 0.42
NFE2L2 Q16236 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23116936 0.90 NR4A3 (0.66) RIPK2NR4A3ALDH1A1HPGDMAPK1
SCHEMBL21366473 0.84 ALDH1A1 (0.62) NR4A3ALDH1A1HPGDKDM4EPOLB
SCHEMBL30153787 0.81 NR4A3 (0.78) RIPK2NR4A3ALDH1A1HPGDSLC9A1
SCHEMBL23135701 0.79 RIPK2 (0.51) RIPK2NR4A3ALDH1A1HPGDSLC9A1
SCHEMBL23135667 0.76 RIPK2 (0.47) RIPK2NR4A3ALDH1A1HPGDSLC9A1
SCHEMBL21366472 0.74 SMN1; SMN2 (0.42) NR4A3ALDH1A1KDM4ESMN1; SMN2MAPK14
SCHEMBL2926133 0.73 MAPK1 (0.73) RIPK2ALDH1A1HPGDSLC9A1SLC9A2
SCHEMBL772176 0.73 NR4A3 (0.57) NR4A3ALDH1A1HPGDMAPK1MAPT
SCHEMBL23116935 0.72 PPARG (0.45) RIPK2NR4A3ALDH1A1HPGDSLC9A1
SCHEMBL21366559 0.72 RIPK2 (0.39) RIPK2NR4A3ALDH1A1HPGDSLC9A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11597702-B2 Substituted pyrazoles FFA4/GPR120 receptor agonists GOLGI NEUROSCIENCES S.R.L. (IT) 2023-03-07 US disclosed
US-11597702-B2 Substituted pyrazoles FFA4/GPR120 receptor agonists GOLGI NEUROSCIENCES S.R.L. (IT) 2023-03-07 US disclosed
US-20210087148-A1 SUBSTITUTED PYRAZOLES FFA4/GPR120 RECEPTOR AGONISTS GOLGI NEUROSCIENCES S.R.L. (IT) 2021-03-25 US disclosed
US-20210087148-A1 SUBSTITUTED PYRAZOLES FFA4/GPR120 RECEPTOR AGONISTS GOLGI NEUROSCIENCES S.R.L. (IT) 2021-03-25 US disclosed
CN-111868035-A Substituted pyrazole FFA4/GPR120 receptor agonists 阿克萨姆股份公司 2020-10-30 CN disclosed
WO-2019175152-A1 SUBSTITUTED PYRAZOLES FFA4/GPR120 RECEPTOR AGONISTS AXXAM S.P.A. (IT) 2019-09-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210087148-A1 SUBSTITUTED PYRAZOLES FFA4/GPR120 RECEPTOR AGONISTS FFAR4, FFAR3, FFAR1 RIPK2 1251/4885NR4A3 91/4885ALDH1A1 1740/4885
US-11597702-B2 Substituted pyrazoles FFA4/GPR120 receptor agonists FFAR4, FFAR3, FFAR1 RIPK2 1251/4885NR4A3 91/4885ALDH1A1 1740/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.